clinical trial · NCT06143878
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Janssen Research & Development, LLC·phase3·active not recruiting·n = 774
Plaque PsoriasisJNJ-77242113JNJ-77242113 Matching PlaceboDeucravacitinibDeucravacitinib Matching Placebo
brief summary
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
started
Jan 17, 2024
primary completion
Sep 17, 2024
completion
Jun 1, 2027
last updated
Sep 21, 2026
official title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol